Professional Marketing briefs: February 2014

Professional Marketing briefs: February 2014
Professional Marketing briefs: February 2014

The Department of Justice has taken an interest in Aegerion Pharmaceuticals, which makes Juxtapid. Aegerion said the government agency has asked for documents surrounding the medication. The ­company got some negative attention in November for comments that its CEO made about Juxtapid on television, but Aegerion says it does not think those comments prompted the DOJ's subpoena.

Obesity drug maker Vivus has secured a marketing-friendly position: preferred brand or non-preferred brand on the Caremark formulary, which will mean co-payments of between $15 and $75 for insured patients whose coverage includes obesity drugs.

Merck is laying off Saphris sales reps. Philly.com reports that the drugmaker will shed the sales force as of February. The layoffs are part of an overhaul that included laying off 8,500 employees and selling Saphris to Forest Laboratories in December.

Gilead's EVP of commercial operations, Kevin Young, has announced his retirement, effective Feb. 4, the biotech firm said. Young's move came just as Gilead is set to launch the HCV treatment Solvadi, which the FDA approved in December.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.